Lilly launches higher dose vials of weight-loss drug

Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points
Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The pharmaceutical company said it has launched 7.5 and 10 milligram single dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram as well as 10 and 12.5 milligram vials.
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also reduced the price of the 2.
Eli Lilly to lower price of Zepbound vials, offer more doses
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells.
New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.
Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.They cost so much partly because of the time and money it took to develop them, Eli Lilly's CEO said.Drugmakers want to capture a fair share of the value they create before patents expire,
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. Novo Nordisk stock is up around 75% despite a pullback in recent months.
Eli Lilly to cut Zepbound single-dose vials to $499 a month from $699 previously
Eli LIlly & Co. said Tuesday it is launching 7.5 and 10 milligram versions of its Zepbound single-dose vials at a price of $499-a-month for self-pay patients, down from $699 previously. The drug giant LLY is also reducing the price of 2.
Yahoo Finance3d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology ...
FiercePharma21h
Lilly banks stockpile of oral GLP-1 drug with potential launch still more than a year away
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Eli Lilly aims to invest in ‘big problems hiding in plain sight' using obesity windfall
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Citi Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...
FiercePharma22h
Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
Is Eli Lilly and Company (LLY) the Top Stock to Buy According to Sustainable Insight Capital Management?
We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...
labiotech22h
Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...